Simone Rancati

Mr. Simone Rancati


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in Diabetology
Verified
Journal Article
Open access
PDF file
SRSimone Rancati
Simone Rancati
PBPietro Bosoni
Pietro Bosoni
RSRICCARDO SCHIAFFINI
RICCARDO SCHIAFFINI
ADAnnalisa Deodati
Annalisa Deodati
PMPaolo Alberto Mongini
Paolo Alberto Mongini
RBRiccardo Bellazzi
Riccardo Bellazzi
Aims: The accurate prediction of blood glucose (BG) levels is critical for managing Type-1 Diabetes (T1D) in pediatric patients, where variability due to factors like physical activity and developmental changes presents significant challenges. Methods: This work explores the application of foundational models, particularly the encoder–decoder model TimeGPT, for BG forecasting in T1D pediatric patients. Methods: The performance of TimeGPT is compared against state-of-the-art models, including ARIMAX and LSTM, and multilayer perceptron (MLP) architectures such as TiDE and TSMixer. The models were evaluated using continuous glucose monitoring (CGM) data and exogenous variables, such as insulin intake. Results: TimeGPT outperforms or achieves comparable accuracy to the state of the art and MLP models in short-term predictions (15 and 30 min), with most predictions falling within the clinically safe zones of the Clarke Error Grid. Conclusions: The findings suggest that foundational models like TimeGPT offer promising generalization capabilities for medical applications and can serve as valuable tools to enhance diabetes management in pediatric T1D patients.

23 September 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
SRSimone Rancati
Simone Rancati
GNGiovanna Nicora
Giovanna Nicora
MPMattia Prosperi
Mattia Prosperi
RBRiccardo Bellazzi
Riccardo Bellazzi
MSMarco Salemi
Marco Salemi
SMSimone Marini
Simone Marini
The COVID-19 pandemic is marked by the successive emergence of new SARS-CoV-2 variants, lineages, and sublineages that outcompete earlier strains, largely due to factors like increased transmissibility and immune escape. We propose DeepAutoCoV, an unsupervised deep learning anomaly detection system, to predict future dominant lineages (FDLs). We define FDLs as viral (sub)lineages that will constitute >10% of all the viral sequences added to the GISAID, a public database supporting viral genetic sequence sharing, in a given week. DeepAutoCoV is trained and validated by assembling global and country-specific data sets from over 16 million Spike protein sequences sampled over a period of ~4 years. DeepAutoCoV successfully flags FDLs at very low frequencies (0.01%–3%), with median lead times of 4–17 weeks, and predicts FDLs between ~5 and ~25 times better than a baseline approach. For example, the B.1.617.2 vaccine reference strain was flagged as FDL when its frequency was only 0.01%, more than a year before it was considered for an updated COVID-19 vaccine. Furthermore, DeepAutoCoV outputs interpretable results by pinpointing specific mutations potentially linked to increased fitness and may provide significant insights for the optimization of public health ‘pre-emptive’ intervention strategies.

2 July 2025 in Briefings in Bioinformatics
Verified
Journal Article
Open access
SRSimone Rancati
Simone Rancati
GNGiovanna Nicora
Giovanna Nicora
LBLaura Bergomi
Laura Bergomi
TBTommaso Mario Buonocore
Tommaso Mario Buonocore
DCDaniel M Czyz
Daniel M Czyz
SMSimone Marini
Simone Marini
Background: The COVID-19 pandemic has caused over 776 million infections and 7 million deaths globally between December 2019 and November 2024. Since the emergence of the original Wuhan strain, SARS-CoV-2 has evolved into multiple variants—including Alpha, Delta, and Omicron—primarily through mutations in the Spike glycoprotein. The S1 subunit, which binds the human angiotensin-converting enzyme 2 (ACE2) receptor, mutates frequently and plays a key role in infectivity and immune escape, while the more conserved S2 subunit mediates membrane fusion. Anticipating future mutations is essential for guiding vaccine design and therapeutic strategies. Generative Large Language Models (LLMs) have shown promise in protein sequence modeling due to their capacity to produce realistic and functional synthetic sequences. Here, we introduce SARITA, a GPT-3-based LLM with up to 1.2 billion parameters, fine-tuned via continual learning on the protein model RITA trained on 107 017 high-quality SARS-CoV-2 Spike sequences (up to March 1st 2021) to generate high-quality synthetic SARS-CoV-2 Spike S1 subunits. Results: SARITA is able to generate realistic, full-length synthetic S1 subunits starting from a 14-amino-acid prompt. When evaluated on unseen sequences collected between March 2021 and November 2023—including major Variants of Concern (VOCs) such as Delta and Omicron, and Variants of Interest such as Iota—SARITA outperforms baseline and state-of-the-art LLMs in terms of sequence quality, biological plausibility, and similarity to real-world viral evolution. SARITA generates high-quality sequences in over 97% of cases, with markedly lower False Mutation Rate and higher similarity scores (PAM30, Levenshtein distance) compared to alternative approaches. It also accurately reproduces key mutations characteristic of future variants—such as L212I, R158L, T95P, and E406K—which were not present in the training data but emerged later in VOCs like Omicron and Delta. Structure-based analysis confirms the functional plausibility of these substitutions, with ΔΔG values within experimentally supported thresholds for ACE2 and antibody binding. Furthermore, SARITA anticipates immune-evasive mutations and accurately captures the positional and statistical distribution of mutations found in post- March 1st 2021 variants, highlighting its potential as a predictive tool for viral evolution. Conclusion: These results indicate the potential of SARITA to predict future SARS-CoV-2 S1 evolution, potentially aiding in the development of adaptable vaccines and treatments.

10 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSimone Rancati
Simone Rancati
GNGiovanna Nicora
Giovanna Nicora
LBLaura Bergomi
Laura Bergomi
TBTommaso Mario Buonocore
Tommaso Mario Buonocore
Daniel CzyzDaniel Czyz
Daniel Czyz
SMSimone Marini
Simone Marini
The COVID-19 pandemic has profoundly impacted global health, economics, and daily life, with over 776 million cases and 7 million deaths from December 2019 to November 2024. Since the original SARS-CoV-2 Wuhan strain emerged, the virus has evolved into variants such as Alpha, Beta, Gamma, Delta, and Omicron, all characterized by mutations in the Spike glycoprotein, critical for viral entry into human cells via its S1 and S2 subunits. The S1 subunit, binding to the ACE2 receptor and mutating frequently, affects infectivity and immune evasion; the more conserved S2, on the other hand, facilitates membrane fusion. Predicting future mutations is crucial for developing vaccines and treatments adaptable to emerging strains, enhancing preparedness and intervention design. Generative Large Language Models (LLMs) are becoming increasingly common in the field of genomics, given their ability to generate realistic synthetic biological sequences, including applications in protein design and engineering. Here we present SARITA, an LLM with up to 1.2 billion parameters, based on GPT-3 architecture, designed to generate high-quality synthetic SARS-CoV-2 Spike S1 sequences. SARITA is trained via continuous learning on the pre-existing protein model RITA. When trained on Alpha, Beta, and Gamma variants (data up to February 2021 included), SARITA correctly predicts the evolution of future S1 mutations, including characterized mutations of Delta, Omicron and Iota variants. Furthermore, we show how SARITA outperforms alternative approaches, including other LLMs, in terms of sequence quality, realism, and similarity with real-world S1 sequences. These results indicate the potential of SARITA to predict future SARS-CoV-2 S1 evolution, potentially aiding in the development of adaptable vaccines and treatments.

8 July 2026
Verified
Book Chapter
Closed access
PDPablo Arozarena Donelli
Pablo Arozarena Donelli
SRSimone Rancati
Simone Rancati
GNGiovanna Nicora
Giovanna Nicora
RBRiccardo Bellazzi
Riccardo Bellazzi
Enea ParimbelliEnea Parimbelli
Enea Parimbelli
Not AvailableNot Available
Not Available

30 June 2026
Verified
Conference Paper
Open access
PDPablo Arozarena Donelli
Pablo Arozarena Donelli
SRSimone Rancati
Simone Rancati
GNGiovanna Nicora
Giovanna Nicora
RBRiccardo Bellazzi
Riccardo Bellazzi
Enea ParimbelliEnea Parimbelli
Enea Parimbelli
Not AvailableNot Available
Not Available